Deep-dive into published cost-effectiveness analyses of semaglutide 2.4 mg from STEP-1: cost per QALY, payer coverage gaps, list vs net pricing, and value calculations for patients considering treatment.
Deep-dive into STEP-1 follow-up and extension data for semaglutide 2.4 mg, covering weight regain after discontinuation, long-term safety signals, and durability of cardiometabolic benefits.
In STEP-1 (NEJM 2021), adults taking semaglutide 2.4 mg lost a mean 14.9% of body weight over 68 weeks vs 2.4% on placebo; about a third lost 20% or more.
A deep dive into the STEP-1 trial's primary and secondary endpoints for semaglutide 2.4 mg, including effect sizes, confidence intervals, response distribution, and week-by-week weight-loss trajectory.
Deep dive into STEP-1 pre-specified and post-hoc subgroup analyses by age, sex, BMI, race, and baseline biomarkers, revealing which patients lost the most weight on semaglutide 2.4 mg.
A detailed critique of the STEP-1 Extension trial examining enrollment biases, follow-up gaps, generalizability concerns, statistical caveats, and conflict-of-interest disclosures around semaglutide discontinuation and weight regain.
A detailed methodological analysis of the STEP-1 Extension trial examining weight regain after semaglutide discontinuation, covering randomization, estimand framework, statistical approach, and interpretive implications.
A deep-dive into the STEP-1 Extension trial showing two-thirds of semaglutide weight loss was regained within one year of stopping treatment, confirming obesity requires ongoing pharmacotherapy.
Deep-dive into the STEP-1 Extension trial results showing weight regain after semaglutide 2.4 mg discontinuation, with effect sizes, secondary endpoints, and time-course analysis.
Deep-dive into STEP-1 Extension pre-specified and post-hoc subgroup analyses by age, sex, BMI, baseline biomarkers, and race/ethnicity, examining differential weight regain after semaglutide discontinuation.
How the STEP-2 trial reshaped prescribing for semaglutide 2.4 mg in type 2 diabetes, which guidelines responded, and what clinicians should consider for patients outside the trial population.
A critical analysis of the STEP-2 semaglutide trial in type 2 diabetes, covering enrollment biases, generalizability gaps, statistical caveats, conflict-of-interest disclosures, and post-publication commentary.
Deep-dive into published cost-effectiveness analyses of semaglutide 2.4 mg from the STEP-2 trial in type 2 diabetes, including cost per QALY, payer coverage, and real-world pricing.
A deep-dive overview of the STEP-2 randomized controlled trial testing semaglutide 2.4 mg for weight loss in adults with type 2 diabetes, including methodology, results, limitations, and clinical implications.
Complete breakdown of the STEP-2 trial results for semaglutide 2.4 mg in type 2 diabetes, including primary and secondary endpoints, confidence intervals, response distribution, and time-course data.
Deep-dive into STEP-2 pre-specified and post-hoc subgroup analyses for semaglutide 2.4 mg in type 2 diabetes, examining differential weight loss by age, sex, BMI, race, and baseline biomarkers.
How the STEP-3 trial of semaglutide 2.4 mg plus intensive behavioral therapy reshapes prescribing decisions, guideline recommendations, and real-world obesity management protocols.
A deep-dive into the enrollment biases, generalizability gaps, statistical caveats, and conflict-of-interest issues in the STEP-3 semaglutide 2.4 mg + intensive behavioral therapy trial.
Deep-dive into STEP-3 follow-up and extension findings for semaglutide 2.4 mg plus intensive behavioral therapy, covering weight regain after discontinuation, durability signals, and long-term safety.
A detailed methodology breakdown of the STEP-3 trial (semaglutide 2.4 mg + intensive behavioral therapy), covering randomization, blinding, estimand framework, inclusion criteria, and how each design choice shapes clinical interpretation.
A deep-dive overview of the STEP-3 trial (2021): semaglutide 2.4 mg combined with intensive behavioral therapy produced 16.0% weight loss vs 5.7% with placebo plus IBT at 68 weeks in adults with overweight or obesity.
Complete breakdown of the STEP-3 trial's primary and secondary endpoints for semaglutide 2.4 mg plus intensive behavioral therapy, including effect sizes, confidence intervals, response distribution, and time-course data.
Deep dive into STEP-3 pre-specified and post-hoc subgroup analyses for semaglutide 2.4 mg plus intensive behavioral therapy, examining differential responses by age, sex, BMI, race, and baseline cardiometabolic markers.
A deep-dive into the STEP-5 trial's 104-week semaglutide data and what it means for real-world prescribing, guideline updates, and long-term obesity pharmacotherapy.
A critical appraisal of the STEP-5 semaglutide trial, covering enrollment biases, generalizability gaps, statistical caveats, conflict-of-interest concerns, and what peer commentary revealed about the 104-week weight-loss data.
A clinical-research deep dive into the STEP-5 trial design, randomization, estimand framework, and statistical choices behind the 104-week semaglutide weight-loss result.
A deep-dive into the STEP-5 randomized controlled trial examining semaglutide 2.4 mg for long-term weight management over 104 weeks, including methodology, results, limitations, and clinical implications.
A deep dive into the STEP-5 trial results for semaglutide 2.4 mg, covering primary and secondary endpoints, effect sizes, confidence intervals, response distribution, and the 104-week time course of weight loss.
A clinical deep-dive into the methodological limitations, enrollment biases, generalizability gaps, and conflict-of-interest considerations of the STEP-8 head-to-head trial comparing semaglutide 2.4 mg to liraglutide 3.0 mg for weight management.
What happened when STEP-8 participants stopped semaglutide 2.4 mg or liraglutide 3.0 mg? Analysis of off-treatment weight regain, durability signals, and long-term safety from the first GLP-1 head-to-head obesity trial.
A deep dive into the STEP-8 trial design, randomization, blinding strategy, estimand framework, and statistical choices that shaped the semaglutide vs liraglutide head-to-head comparison.
A detailed plain-English breakdown of the STEP-TEENS trial, which tested semaglutide 2.4 mg in adolescents with obesity and found 16.1% weight loss versus 0.6% with placebo.
A clinical deep-dive into the SUNRISE-1 trial of lemborexant for insomnia, examining what the results mean for real-world prescribing decisions, guideline updates, and patient selection beyond the abstract.
A critical analysis of the SUNRISE-1 trial's enrollment biases, follow-up duration, generalizability gaps, statistical caveats, and conflict-of-interest considerations for lemborexant in insomnia.
Health-economic analysis of lemborexant based on SUNRISE-1 trial data: cost per QALY, payer coverage patterns, WAC vs net pricing, and patient-level value calculations for insomnia treatment.
Deep-dive into SUNRISE-1 long-term extension findings for lemborexant in insomnia: durability of sleep onset latency improvements, safety signals over 12 months, and what the follow-up data reveal about sustained efficacy.
A deep-dive into the SUNRISE-1 randomized controlled trial that tested lemborexant against placebo and zolpidem for insomnia, leading to FDA approval of a dual orexin receptor antagonist.
Deep-dive into SUNRISE-1 trial results for lemborexant (Dayvigo) in insomnia: primary and secondary endpoints, effect sizes, confidence intervals, time-course data, and response distribution analysis.
Deep-dive into SURMOUNT-1 follow-up and extension findings for tirzepatide, covering weight regain after discontinuation, durability of cardiometabolic benefits, and emerging long-term safety signals.
A detailed breakdown of SURMOUNT-1's randomization, blinding, estimand framework, and statistical design, and why each methodological choice matters for interpreting tirzepatide's 20.9% weight-loss result.
A plain-English deep dive into the SURMOUNT-1 trial, explaining how tirzepatide achieved up to 20.9% weight loss in adults with obesity and what that means for clinical practice.
A deep dive into the SURMOUNT-1 trial results for tirzepatide 5, 10, and 15 mg, covering primary and secondary endpoints, confidence intervals, weight-loss time course, and response distribution data beyond the abstract.
A deep-dive into the SURMOUNT-2 trial of tirzepatide in type 2 diabetes, examining which guidelines shifted, how prescribing patterns changed, and what the results mean for real-world patients.
A deep-dive into the enrollment biases, generalizability gaps, statistical caveats, and conflict-of-interest issues in the SURMOUNT-2 trial of tirzepatide for weight loss in type 2 diabetes.
Deep-dive into SURMOUNT-2 follow-up and extension findings for tirzepatide in type 2 diabetes, covering durability of weight loss, weight regain after discontinuation, and long-term safety signals.
A deep-dive into the SURMOUNT-2 trial design, randomization, estimand framework, and statistical choices that shaped tirzepatide's weight-loss results in type 2 diabetes.
A clear, evidence-based overview of the SURMOUNT-2 trial, which tested tirzepatide for weight loss in adults with type 2 diabetes and obesity. Covers study design, key results, limitations, and clinical relevance.
A deep-dive into the SURMOUNT-2 trial results for tirzepatide in type 2 diabetes, covering primary and secondary endpoints, effect sizes, confidence intervals, response distributions, and the weekly weight-loss trajectory.
Deep-dive into SURMOUNT-2 pre-specified and post-hoc subgroup analyses for tirzepatide in type 2 diabetes: responses by age, sex, BMI, race, and baseline biomarkers.
Health-economic analyses of SURMOUNT-3: cost per QALY for tirzepatide after intensive lifestyle intervention, payer-coverage barriers, list-price vs net-price gaps, and value considerations for patients and clinicians.
Analysis of SURMOUNT-3 long-term follow-up, weight regain patterns after tirzepatide discontinuation, durability of cardiometabolic benefits, and what the trial's design tells us about sustained obesity treatment.
SURMOUNT-3: adults who lost 5%+ weight via 12-week lifestyle program lost 21.1% more with tirzepatide vs 3.3% with placebo over 72 weeks.
Detailed breakdown of the SURMOUNT-3 trial results for tirzepatide after intensive lifestyle intervention, including effect sizes, confidence intervals, secondary endpoints, and response distribution.
Deep-dive into SURMOUNT-4's clinical implications for tirzepatide prescribing: weight regain data, guideline updates, and what the trial means for real-world patients.
A critical analysis of SURMOUNT-4's enrollment biases, follow-up duration, generalizability gaps, statistical caveats, and conflict-of-interest considerations for tirzepatide weight maintenance.
Health-economic analysis of tirzepatide continuation vs discontinuation from SURMOUNT-4, including cost per QALY estimates, payer coverage dynamics, and individual value calculations.
Deep-dive into SURMOUNT-4 follow-up findings on tirzepatide weight regain after discontinuation, durability of effect, and long-term safety signals from the 2024 JAMA trial.
A detailed breakdown of the SURMOUNT-4 trial design, randomized withdrawal methodology, estimand framework, and statistical choices that shaped tirzepatide's weight-regain data.
A granular breakdown of SURMOUNT-4 trial results for tirzepatide, including primary and secondary endpoint data with confidence intervals, weight-regain kinetics on placebo switch, and response distribution across subgroups.
Deep-dive into SURMOUNT-4 pre-specified and post-hoc subgroup analyses for tirzepatide weight maintenance, examining differential responses by age, sex, BMI, race, and baseline biomarkers.